We are live on
!
Find out more
SB
Samsara BioCapital Portfolio holdings
AUM
$1.03B
1-Year Est. Return
214.94%
This Fund
S&P 500
This Quarter
Est. Return
+36.87%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$311M
AUM Growth
+$137M
(+79%)
Cap. Flow
+$83.9M
Cap. Flow
% of AUM
26.99%
Top 10 Holdings %
Top 10 Hldgs %
74.66%
Holding
36
New
8
Increased
5
Reduced
10
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
+$68.4M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$10.4M |
| 3 |
Spyre Therapeutics
SYRE
|
+$7.37M |
| 4 |
Geron
GERN
|
+$5.82M |
| 5 |
Sutro Biopharma
STRO
|
+$5.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Liquidia Corp
LQDA
|
+$4.78M |
| 2 |
Tempest Therapeutics
TPST
|
+$3.97M |
| 3 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$3.59M |
| 4 |
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
|
+$2.46M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$2.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLNO
26
DELISTED
Soleno Therapeutics
SLNO
| $1.67M | 0.54% |
+50,000
| New | +$2.17M |
|
|
UROV
27
DELISTED
Urovant Sciences Ltd.
UROV
| $1.55M | 0.5% |
157,480
| – | – |
|
|
NGM
28
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $959K | 0.31% |
+48,602
| New | +$929K |
|
29
Assembly Biosciences
ASMB
$531M
| $694K | 0.22% |
+2,478
| New | +$578K |
|
|
AKRO
30
DELISTED
Akero Therapeutics
AKRO
| $554K | 0.18% |
22,234
-27,766
| -56% | -$635K |
|
|
AMRN
31
Amarin Corp
AMRN
$302M
| $346K | 0.11% |
2,500
-7,260
| -74% | -$999K |
|
|
VRNA
32
DELISTED
Verona Pharma
VRNA
| $203K | 0.07% |
+43,456
| New | +$201K |
|
|
BLUE
33
DELISTED
bluebird bio
BLUE
| – | – |
-1,914
| Closed | -$1.14M |
|
|
34
Liquidia Corp
LQDA
$8B
| – | – |
-1,013,773
| Closed | -$4.78M |
|
|
35
Tempest Therapeutics
TPST
$14.6M
| – | – |
-3,853
| Closed | -$3.97M |
|
|
VIRX
36
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – |
-169,663
| Closed | -$2.46M |
|
Similar funds
MA
WHCM
JSC
GSIS
IAS
CM
CFFNO
MSA
Samsara BioCapital's Q2 2020 Portfolio in Review
As of Q2 2020, Samsara BioCapital held 36 positions worth $311M, up 79% from $174M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Samsara BioCapital deployed $83.9M of net new capital in Q2 2020, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,578,388 shares worth $73.4M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.
On the sell side, the largest reduction was Principia Biopharma Inc. Common Stock, an estimated $3.59M trimmed.
- Samsara BioCapital's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,578,388 shares worth $73.4M.
- Samsara BioCapital added most to IVERIC bio, Inc. Common Stock in Q2 2020, an estimated $10.4M increase.
- Samsara BioCapital's biggest Q2 2020 reduction was Principia Biopharma Inc. Common Stock, cutting an estimated $3.59M.
- Samsara BioCapital fully exited Liquidia Corp in Q2 2020, selling an estimated $4.78M.
- Samsara BioCapital's ten largest holdings make up 75% of its $311M portfolio in Q2 2020.
- Samsara BioCapital opened 8 new positions and closed 4 in Q2 2020.
- Samsara BioCapital's portfolio value rose 79% quarter-over-quarter to $311M.
Based on Samsara BioCapital's 13F filing for Q2 2020, filed 14 Aug 2020.